|
| 38042367 | A case of fatal monkeypox infection: necropsy and molecular findings, with some considerations related to clinical management. | Clin Microbiol Infect | 2024 |
| 36791667 | A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). | Eur J Cancer | 2023 |
| 37291203 | ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma. | Nat Commun | 2023 |
| 37007636 | Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). | Ther Adv Med Oncol | 2023 |
| 37298296 | VE-Cadherin in Cancer-Associated Angiogenesis: A Deceptive Strategy of Blood Vessel Formation. | Int J Mol Sci | 2023 |
| 36464647 | Datasets for the reporting of primary tumour in bone: recommendations from the International Collaboration on Cancer Reporting (ICCR). | Histopathology | 2023 |
| 36603685 | Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma. | Biochem Pharmacol | 2023 |
| 36797281 | VE-Cadherin modulates β-catenin/TCF-4 to enhance Vasculogenic Mimicry. | Cell Death Dis | 2023 |
| 34560242 | Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2022 |
| 35593180 | Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective. | Expert Rev Pharmacoecon Outcomes Res | 2022 |
| 35354905 | Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1. | Oncogene | 2022 |
| 36551696 | Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma. | Cancers (Basel) | 2022 |
| 36467415 | Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness. | Front Cell Dev Biol | 2022 |
| 36202860 | Small round cell sarcomas. | Nat Rev Dis Primers | 2022 |
| 36358891 | Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies. | Cancers (Basel) | 2022 |
| 35955799 | Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell-Matrix Interactions. | Int J Mol Sci | 2022 |
| 36221013 | Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma. | Cell Mol Life Sci | 2022 |
| 36115869 | An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. | NPJ Precis Oncol | 2022 |
| 33875457 | Molecular diagnosis in non-small-cell lung cancer: expert opinion on <i>ALK</i> and <i>ROS1</i> testing. | J Clin Pathol | 2022 |
| 35152364 | Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP). | Clin Transl Oncol | 2022 |
| 34974029 | SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. | J Control Release | 2022 |
| 29932342 | The bitter side of epigenetics: variability and resistance to chemotherapy. | Epigenomics | 2021 |
| 33919988 | Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. | J Clin Med | 2021 |
| 33581682 | Selective modulation by PARP-1 of HIF-1α-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions. | Redox Biol | 2021 |
| 33804796 | Endoglin in the Spotlight to Treat Cancer. | Int J Mol Sci | 2021 |
| 34500044 | Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2021 |
| 34544555 | [Multidisciplinary consensus on optimizing the detection of NTRK gene alterations in tumours]. | Rev Esp Patol | 2021 |
| 34680383 | Evaluation of <i>NAB2-STAT6</i> Fusion Variants and Other Molecular Alterations as Prognostic Biomarkers in a Case Series of 83 Solitary Fibrous Tumors. | Cancers (Basel) | 2021 |
| 34621020 | E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. | Oncogene | 2021 |
| 34303806 | Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>â¿¿</sup>. | Ann Oncol | 2021 |
| 34345016 | Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma. | Oncogene | 2021 |
| 34150764 | Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma. | Front Cell Dev Biol | 2021 |
| 34090171 | Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. | ESMO Open | 2021 |
| 33326093 | (Immuno)histological Analysis of Ewing Sarcoma. | Methods Mol Biol | 2021 |
| 33479225 | Sarcoma classification by DNA methylation profiling. | Nat Commun | 2021 |
| 32225029 | Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape. | Cells | 2020 |
| 32030654 | Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. | Clin Transl Oncol | 2020 |
| 32066540 | Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2020 |
| 31911079 | LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity. | Cancer Lett | 2020 |
| 31880317 | Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma. | J Pathol | 2020 |
| 33217932 | Both Epimutations and Chromosome Aberrations Affect Multiple Imprinted Loci in Aggressive Wilms Tumors. | Cancers (Basel) | 2020 |
| 33024443 | Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. | Front Genet | 2020 |
| 33097530 | RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis. | Sci Adv | 2020 |
| 33203665 | Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. | J Immunother Cancer | 2020 |
| 32888360 | Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. | Oncologist | 2020 |
| 33012494 | [Liquid biopsy in oncology: A consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology]. | Rev Esp Patol | 2020 |
| 32420057 | From precision medicine to imprecision medicine through limited diagnostic ability to detect low allelic frequency mutations. | Transl Lung Cancer Res | 2020 |
| 32245434 | Clinical performance evaluation of the Idyllaâ¿¢ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer. | BMC Cancer | 2020 |
| 32502203 | An inducible ectopic expression system of EWSR1-FLI1 as a tool for understanding Ewing sarcoma oncogenesis. | PLoS One | 2020 |
| 32497782 | Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution. | J Control Release | 2020 |